Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Published:2023-01 Issue:10371 Volume:401 Page:105-117
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hurvitz Sara A,Hegg Roberto,Chung Wei-Pang,Im Seock-Ah,Jacot William,Ganju Vinod,Chiu Joanne Wing Yan,Xu Binghe,Hamilton Erika,Madhusudan Srinivasan,Iwata Hiroji,Altintas Sevilay,Henning Jan-Willem,Curigliano Giuseppe,Perez-Garcia José Manuel,Kim Sung-Bae,Petry Vanessa,Huang Chiun-Sheng,Li Wei,Frenel Jean-Sebastien,Antolin Silvia,Yeo Winnie,Bianchini Giampaolo,Loi Sherene,Tsurutani Junji,Egorov Anton,Liu Yali,Cathcart Jillian,Ashfaque Shahid,Cortés Javier

Funder

AstraZeneca

Daiichi-Sankyo

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012

2. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

4. Antibody–drug conjugates in breast cancer: the chemotherapy of the future?;Nicolò;Curr Opin Oncol,2020

5. Trastuzumab emtansine: mechanisms of action and drug resistance;Barok;Breast Cancer Res,2014

Cited by 279 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer;Drug Resistance Updates;2024-11

2. The advancements and prospective developments in anti-tumor targeted therapy;Neoplasia;2024-10

3. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals;The Breast;2024-10

4. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial;Nature Medicine;2024-09-13

5. ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms;Die Onkologie;2024-09-13